首页> 外文OA文献 >AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer

【2h】

AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer

机译：Ar-V7雄激素受体变体作为用于治疗阉割 - 难治转移前列腺癌的雄激素受体靶向剂的预测因子

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tomáš Büchler; Vladimír Bobek; Katarína Kološtová;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer [J] . To Sarah Q., Kwan Edmond M., Fettke Heidi C., European urology . 2018,第6期

机译：全血中雄激素受体剪接变体7或9的表达不会预测对转移阉割抗阉割前列腺癌中的雄激素轴靶向剂的反应
2. Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149–56. AR-V7 Testing: What's in it for the Patient? [J] . Jun Luo, Brandon Luber, Hao Wang, European urology . 2017,第6期

机译：回复Julie Steinestel，Christof Bernemann，Andres J. Schrader，Jochen K. Lennerz的信Re：Emmanuel S. Antonarakis，ChangXue Lu，Brandon Luber等。雄激素受体剪接变异-7 mRNA检测在用第一和二线依甲酰丁酰胺处理的转移性阉割前列腺癌循环肿瘤细胞中的胃泌素受体剪接变异-7mRNA检测。 J Clin incol 2017; 35：2149-56。 AR-V7测试：患者中有什么？
3. CLINICAL RESPONSE AND TIME TO PROSTATE-SPECIFIC ANTIGEN (PSA) PROGRESSION IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING SECOND-LINE CHEMOTHERAPY VERSUS ALTERNATIVE ANDROGEN RECEPTOR-TARGETED AGENTS (ARTA) AFTER A LACK OF RESPONSE TO FIRST-LINE ARTA IN US COMMUNITY ONCOLOGY PRACTICES [J] . Oh W. K., Cheng W. Y., Miao R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：在缺乏对第一线ARTA缺乏反应之后，转移阉割抗性前列腺癌（MCRPC）接受二线化疗的患者前列腺特异性抗原（PSA）进展的临床响应和时间在美国社区肿瘤学实践中
4. Novel Strategies for Targeting the Androgen-Receptor Axis: PARP1 as a Mediator of Androgen Receptor-Dependent Transcriptional Control [C] . Karen E. Knudsen Genitourinary Cancers Symposium . 2013

机译：靶向雄激素受体轴的新策略：PARP1作为雄激素受体依赖性转录控制的介质
5. Targeting CD133 in Androgen Receptor Indifferent, Neuroendocrine Differentiated Aggressive Variant Prostate Cancer [D] . Glumac, Paige M. 2019

机译：在雄激素受体无关，神经内分泌分化型侵袭性前列腺癌中靶向CD133
6. Role of Circulating Tumor Cells (CTC) Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients [O] . Carlo Cattrini, Alessandra Rubagotti, Linda Zinoli, 2019

机译：循环肿瘤细胞（CTC）雄激素受体全长（AR-FL）和雄激素受体剪接变体7（AR-V7）在去势抵抗性转移性前列腺癌患者的预期队列中的作用
7. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry [O] . Malou C.P. Kuppen, Hans M. Westgeest, Alphonsus J.M. van den Eertwegh, 2019

机译：序列雄激素受体的现实世界结果靶向有或没有插入的寿命抵抗前列腺癌中的寿命延长药物：荷兰阉割前列腺癌登记处的结果

AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅